Gilead Sciences buys Immunomedics for $21 billion
The deal marks Gilead’s largest-ever purchase, and its fourth major acquisition since the coronavirus pandemic began.
California-based pharmaceutical behemoth Gilead Sciences has acquired cancer-drug developer Immunomedics for $21 billion, causing the latter’s share price to double.
Having recently become a commercial-stage biopharmaceuticals company after the Food and Drug Administration (FDA) approved its drug Trodelvy as a third-line breast cancer treatment, Immunomedics had a market cap of less than half of what Gilead eventually ended up paying. The reason for the premium was that the purchase would bring Gilead its first de-risked solid tumour oncology programme, with a drug that had already enjoyed sales of $20 million since its launch in Q2. Trodelvy sales are expected to reach $2.3 billion by 2026.
The drug works by directly delivering chemotherapy to tumour cells whenever it recognises a particular protein, Trop-2, on the surface of those cells. It is the first available treatment for patients with triple-negative breast cancer, and could treat patients with pancreas and bladder cancer, which also often feature the Trop-2 protein.
Despite the clear promise of the drug, analysts do not all agree that its entry into Gilead’s stable justifies Immunomedics’s steep asking price, especially given that high-promise drugs such as remdesivir and filgotinib are now underperforming for commercial and regulatory reasons respectively.
Nonetheless, Gilead’s move into oncology is a strategic one, and one that will – given the drug’s projected sales – reap big profits in the years to come.
Legal advisor to Gilead Sciences: Davis Polk & Wardwell
Financial advisor to Gilead Sciences: Lazard, Morgan Stanley
Legal advisor to Immunomedics: Wachtell, Lipton, Rosen & Katz
Financial advisor to Immunomedics: Centerview Partners, BofA Securities
The European Commission’s approval of the copyright directive in April threw more gas on the fire. In a few years, the internet has become – among other things – the main market fo...
The long-serving boss of Cobepa, Jean-Marie Laurent Josi talks about the business model of a Belgian investment firm that is trusted by major European families, one which marries t...
Since the last half of 2008, it is no longer possible to conceal the term ‘crisis’. New paradigms have become apparent and structural changes are predicted. Indeed mar...